Market Place
Sourcing Support
ERS Genomics Launches ‘Express License’ For CRISPR/Cas9 Access
13 Jan 2025 //
GLOBENEWSWIRE
ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement
04 Sep 2024 //
BUSINESSWIRE
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
20 May 2024 //
BUSINESSWIRE
ERS Genomics Appoints John E Milad as Chief Executive Officer
13 May 2024 //
BUSINESSWIRE
ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement
18 Sep 2023 //
PR NEWSWIRE
ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement
14 Sep 2023 //
PR NEWSWIRE
Crown Bioscience inks deal with ERS for gene editing technology
12 Dec 2022 //
FIERCEBIOTECH
Crown and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement
08 Dec 2022 //
BUSINESSWIRE
Crown Bioscience, ERS Genomics Ink Global CRISPR/Cas9 Licensing Agreement
08 Dec 2022 //
CONTRACTPHARMA
New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL
17 Nov 2022 //
BUSINESSWIRE
ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement
25 Jul 2022 //
PRNEWSWIRE
Sumitomo Pharma takes license to CRISPR/Cas9 patent portfolio from ERS Genomics
28 Apr 2022 //
BIOSPECTRUMASIA
ERS Genomics and Cellular Engineering Technologies sign a license agreement.
17 Aug 2021 //
BUSINESSWIRE
ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement
26 Jul 2021 //
BUSINESSWIRE
ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement
30 Jun 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.